Why Aishwarya Mohanraj Named Mounjaro And Then Warned Everyone About It

When comedian and content creator Aishwarya Mohanraj uploaded a YouTube video admitting she used Eli Lilly’s Mounjaro injections for weight loss, she did something unusual for an Indian public figure. She said the name directly, not hormonal support, not medical treatment and not even vague transformation talk. She said Mounjaro and then she warned her audience not to copy her.

The 22 kg loss Reveal! But Not the Way You Expected

In the video, Aishwarya shared that she lost over 20–22 kgs in six months under medical supervision. She traced her weight gain back to her late twenties, pointing to underlying health conditions such as PCOS, insulin resistance, hypothyroidism and clinical depression.

She explained that sustained weight loss had been difficult despite workouts, dietary changes and professional support. Injuries interrupted her training. Hormones complicated her progress. Mental health affected consistency.

After a medical review earlier in 2025, she began taking Mounjaro, a once-weekly injectable originally prescribed for type 2 diabetes and chronic weight management.

The results were dramatic, but she was clear: it was not effortless.

She spoke about nausea in the early weeks, intense appetite suppression, hair loss linked to rapid weight reduction and the financial cost of treatment. She also mentioned an unexpected shift; her menstrual cycle became regular after years of inconsistency. And then she made her main point, that this route should not be a shortcut.

Why Her Warning Matters

Her rapid weight loss has increasingly sparked speculation around GLP-1 drugs globally. GLP-1 receptor agonists are a class of injectable or oral medications that mimic the GLP-1 hormone to manage type 2 diabetes, promote weight loss and reduce cardiovascular risks. But in India, very few public figures have openly acknowledged using them. By naming Mounjaro, Aishwarya shifted the conversation from gossip to first-person disclosure.

At the same time, she repeatedly told viewers not to turn to influencers for medical advice. She urged people to consult doctors instead of copying what they see online. That caution is significant because GLP-1 medications are not lifestyle supplements; they are prescription drugs.

Soha Ali Khan Steps In

Actor Soha Ali Khan praised Aishwarya on Instagram for speaking openly.

“So finally someone said it. They lost a ton of weight not just by eating right or working out, but by taking Mounjaro. And I think it takes great courage to speak the truth,” she wrote.

View this post on Instagram

A post shared by Soha (@sakpataudi)

Soha emphasised that Ozempic and Mounjaro are not trends. They are serious medical treatments meant for specific individuals. She highlighted that weight loss is influenced by hormones, insulin resistance, PCOS, thyroid and metabolism, not just willpower.

She added that injections can help but come with side effects, testing requirements and medical supervision. Instead of asking who is taking it, she said, people should ask who truly needs it.

Soha also announced that her podcast All About Her will feature endocrinologist Dr Ambrish Mithal and nutritionist Dr Juhi Agarwal to discuss the science, risks and myths surrounding these drugs.

The Female-Led Podcasts Redefining India’s Listening Culture

What Exactly Is Mounjaro?

Mounjaro’s generic name is Tirzepatide. It is a GLP-1 and GIP receptor agonist. Ozempic, on the other hand, contains Semaglutide and acts only as a GLP-1 receptor agonist.

GLP-1 drugs mimic glucagon-like peptide 1, a hormone produced in the small intestine. These medications increase insulin production, slow gastric emptying and reduce appetite, helping regulate blood sugar and induce weight loss.

According to endocrinologist Dr Narendra BS from Aster Whitefield, Tirzepatide works on two appetite-suppressing hormones, GLP-1 and GIP. Clinical trials such as the SURMOUNT studies have shown double-digit percentage weight losses over 72 weeks in non-diabetic individuals.

But prescription criteria are strict.

These drugs are typically recommended for adults with obesity defined as a BMI of 30 or above, or a BMI of 27 with at least one obesity-related condition. They are used alongside diet and exercise, not instead of them.

What Makes It Alarming?

The concern is not the drug alone. It is the narrative around it.

Research in rodents has linked Tirzepatide to thyroid C-cell tumours, leading to boxed warnings. It is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2. Caution is advised for those with pancreatitis, severe kidney disease or gastroparesis. It is not recommended during pregnancy.

Common side effects include nausea, vomiting and diarrhoea. Some patients discontinue because of these.

There are also broader issues: high cost, limited accessibility, risk of pancreatitis and gallbladder disease, and the pattern of weight regain once treatment stops.

Doctors emphasise that these injections are medical interventions, not aesthetic fixes.

The Marketing Shift: Education Over Glamour

Aishwarya’s disclosure landed at a time when Eli Lilly has been running obesity-awareness campaigns in India that focus on science rather than shame.

Because direct-to-consumer advertising of prescription medicines is restricted in India, pharmaceutical companies rely on disease awareness messaging instead of product promotion.

Influencer transparency, even when independent of brand partnerships, becomes organic category education.

Read Full Story here: ASCI Compliance Will Be Mandatory for Influencers in 2026

Instead of rumours about “secret injections,” audiences are hearing terms like insulin resistance, hormonal imbalance and metabolic health.

That is a cultural shift.